Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Outline of Final Research Achievements |
ATBF1 levels are increased in the cytoplasm of hippocampal neurons in Alzheimer’s disease (AD) brains compared with non-AD brains. Furthermore, cotransfection of human embryonic kidney (HEK293T) and human neuroblastoma (SH-SY5Y) cells with ATBF1 and APP695 increased steady-state levels of APP via the binding of ATBF1 to the APP cytoplasmic domain (amino acids 681-690 domain), resulting in increased Aβ production and cellular and soluble APP (sAPP) levels without affecting the activity or levels of APP processing enzymes (α-, β- or γ-secretase). Conversely, knockdown of endogenous ATBF1 reduced levels of cellular APP, sAPP and Aβ in HEK293 cells overexpressing human APP695. Our findings provide insight into the dynamics of APP processing and Aβ production, and suggest that ATBF1 is a novel APP binding protein that may be a suitable therapeutic target for AD.
|